The study by Tee et al,1 which was first published online last November in the Archives, convincingly shows that the use of bisphosphonates in patients who are receiving long-term steroid therapy for bullous diseases can reduce steroid-induced osteoporosis. This is equally true for nonbullous diseases, as has been demonstrated in many placebo-controlled randomized trials reported in the medical literature. Numerous studies have also demonstrated poor bisphosphonate implementation in populations at risk for glucocorticoid-induced osteoporosis.